Imfinzi + nya immunoterapier förbättrade kliniska utfall vid icke resekterbar NSCLC i stadium III

Imfinzi combined with novel immunotherapies improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer

COAST Phase II trial showed oleclumab or monalizumab in combination with Imfinzi significantly delayed disease progression and increased objective response rate.

Läs hela pressmeddelandet på engelska här